3 results
The primary objective is to demonstrate the superior efficacy of telaprevir in combination withPeg-IFN alfa-2a and RBV compared to standard treatment in subjects with chronic HCVgenotype 1 infection who failed prior treatment with Peg-IFN plus RBV.…
To characterize safety, tolerability, pharmacodynamic effects, and pharmacokinetics of the oral sGC stimulator BAY 1021189 in addition to standard therapy for heart failure with reduced EF (HFrEF) over 12 weeks in patients with worsening chronic…
The primary objective is to compare doxorubicin plus olaratumab versus doxorubicin plus placebo with respect to OS in patients with advanced or metastatic soft tissue sarcoma (STS) or advanced or metastatic leiomyosarcoma (LMS), not amenable to…